New combo therapy targets tough lung cancer

NCT ID NCT06246110

Ongoing Disease control Sponsor: Eikon Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called EIK1001 combined with standard treatments (pembrolizumab and chemotherapy) in 70 people with stage 4 non-small cell lung cancer who haven't had prior treatment. The main goal is to check safety and side effects, while also seeing how well the tumors shrink. This is not a cure, but aims to better control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Accelacare of Duly

Tinley Park, Illinois, 60487, United States
Albert Einstein College of Medicine, Jacobi Medical Center

The Bronx, New York, 10461, United States
Atlanta Piedmont Hospital

Atlanta, Georgia, 30318, United States
Baptist Cancer Center

Memphis, Tennessee, 38120, United States
Bioresearch Partner

Hialeah, Florida, 33013, United States
Blue Ridge Cancer Care Oncology Associates SW VA

Blacksburg, Virginia, 24060, United States
California Cancer Care Associates for Research & Excellence

Fresno, California, 93720, United States
California Research Institute

Los Angeles, California, 90027, United States
Cancer Center of Kansas

Wichita, Kansas, 67214, United States
Cancer and Blood Specialists of New York, White Plains Hospital

White Plains, New York, 10601, United States
Gabrail Cancer Center

Canton, Ohio, 44718, United States
Health Midwest Oncology Associates of Kansas

Overland Park, Kansas, 66211, United States
Illinois Cancer Specialists

Niles, Illinois, 60714, United States
Indiana University Cancer Center

Indianapolis, Indiana, 46202, United States
Ironwood Cancer and Research Center

Chandler, Arizona, 85224, United States
Jersey Shore University Medical Center/Meridian Hematology & Oncology

Neptune City, New Jersey, 07753, United States
Kaiser Permanente Hawaii

Honolulu, Hawaii, 96819, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, 10016, United States
Maryland Oncology

Columbia, Maryland, 20144, United States
Medstar Franklin Square Cancer Center at Loch Raven Campus

Baltimore, Maryland, 21237, United States
Memorial Cancer Institute

Hollywood, Florida, 33021, United States
Messino Cancer Centers

Asheville, North Carolina, 28806, United States
Mid-Florida Hematology and Oncology Center

Orange, Florida, 32763, United States
New York Cancer and Blood Specialists

Babylon, New York, 11702, United States
Orlando Health Cancer Institute

Orlando, Florida, 32806, United States
Providence St Joseph Hospital, Center for Cancer Prevention and Treatment

Orange, California, 92868, United States
Rocky Mountain Cancer

Lone Tree, Colorado, 80124, United States
Shenandoah Oncology

Winchester, Virginia, 22601, United States
Southern Cancer Care

Daphne, Alabama, 36608, United States
Sutter Health Institute for Medical Research

Sacramento, California, 95816, United States
Tennessee Cancer Specialists

Knoxville, Tennessee, 37909, United States
Texas Oncology, Austin

Austin, Texas, 78745, United States
Texas Oncology, Bedford

Bedford, Texas, 76022, United States
The Center for Cancer and Blood Disorders

Fort Worth, Texas, 76104, United States
University of Southern California, Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States
Weil Cornell Medical Center

New York, New York, 10022, United States
Willamette Valley

Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.